Oculis (OCS) Short Interest Ratio & Short Volume

Short interest is the volume of Oculis shares that have been sold short but have not yet been covered or closed out. As of July 31st, investors have sold 9,600 shares of OCS short. 0.03% of Oculis' shares are currently sold short. Learn More on Oculis' current short interest.

Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 0.03% of Oculis' floating shares are currently sold short.

Oculis saw a decline in short interest in the month of July. As of July 31st, there was short interest totaling 9,600 shares, a decline of 54.1% from the previous total of 20,900 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

Oculis currently has issued a total of 43,660,000 shares. Some of Oculis' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Oculis currently has a public float of 34,950,000 shares.

0.03% of Oculis' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Oculis: Protagonist Therapeutics, Inc. (9.74%), Apellis Pharmaceuticals, Inc. (18.71%), Scholar Rock Holding Corporation (17.84%), Mirum Pharmaceuticals, Inc. (15.41%), NewAmsterdam Pharma Company N.V. (11.51%), AMNEAL PHARMACEUTICALS, INC. (3.42%), Ultragenyx Pharmaceutical Inc. (8.39%), Kymera Therapeutics, Inc. (14.17%), Immunovant, Inc. (23.94%), HUTCHMED (China) Limited Sponsored ADR (0.23%),

As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($70.87 billion), Invesco QQQ ($30.12 billion), iShares Russell 2000 ETF ($19.85 billion), iShares 20+ Year Treasury Bond ETF ($10.34 billion), Strategy Inc ($8.98 billion), iShares iBoxx $ Investment Grade Corporate Bond ETF ($7.61 billion), SPDR S&P Biotech ETF ($6.81 billion), Invesco S&P 500 Equal Weight ETF ($6.14 billion), Palo Alto Networks, Inc. ($5.97 billion), and Super Micro Computer, Inc. ($5.28 billion). View all of the most shorted stocks.

Short selling OCS is an investing strategy that aims to generate trading profit from Oculis as its price is falling. OCS shares are trading up $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

A short squeeze for Oculis occurs when it has a large amount of short interest and its stock increases in price. This forces short sellers to cover their short interest positions by buying actual shares of OCS, which in turn drives the price of the stock up even further.

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including OCS, twice per month. The most recent reporting period available is July, 31 2025.